Table 1.
Summary of sample information
| Dataset | Sample size | AD status (AD/controls) | Gender (male/female) | Genotyping chip | Mean AAD (AD/controls) | Origin |
|---|---|---|---|---|---|---|
| Mayo | 434 | 220/214 | 246/188 | Illumina 300 | 73.5/71.7 | USA |
| NIMH | 46 | 46/0 | 12/34 | Illumina 610 | 78.1/- | USA |
| WashU | 332 | 294/38 | 140/192 | Illumina 610 | 84.1/86.1 | USA |
| Belfast | 235 | 213/22 | 99/136 | Illumina 610 | 82.2/83.1 | UK |
| Bristol | 59 | 43/16 | 21/38 | Illumina 610 | 82.5/81.6 | UK |
| London | 238 | 194/44 | 83/155 | Illumina 610 | 86.1/83.0 | UK |
| Manchester | 1 | 1/0 | 0/1 | Illumina 610 | 79.0/- | UK |
| Nottingham | 39 | 35/4 | 18/21 | Illumina 610 | 83.6/79.5 | UK |
| Oxford | 1 | 1/0 | 0/1 | Illumina 610 | 79.5/- | UK |
| Pooled | 1385 | 1047/338 | 619/766 | — | 81.5/76.1 | — |
Genome-wide association studies (GWAS) data were obtained from a total of 9 centers, 3 from the USA (NIMH, WashU, and Mayo) and 6 from the UK (Nottingham, Bristol, Manchester, Belfast, Oxford, and London). Sample size, number of cases and controls, and gender for each cohort are as indicated together with details of the mean age at death in years for cases and controls and the genotyping chip used in each study. “-” means the information is not applicable.
Key: AAD, age at death; AD, Alzheimer’s disease; NIMH, National Institute of Mental Health; WashU, Washington University.